Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial Meeting Abstract
| Authors: | Javle, M. M.; Borbath, I.; Clarke, S. J.; Hitre, E.; Louvet, C.; Mercade, T. M.; Oh, D. Y.; Spratlin, J. L.; Valle, J. W.; Weiss, K. H.; Berman, C.; Howland, M.; Ye, Y.; Cho, T.; Moran, S.; Abou-Alfa, G. K. |
| Abstract Title: | Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial |
| Meeting Title: | 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2019 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-05-20 |
| Start Page: | 259s |
| Language: | English |
| ACCESSION: | WOS:000487345803339 |
| DOI: | 10.1200/JCO.2019.37.15_suppl.TPS4155 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS4155 -- Source: Wos |
